BRIEF published on 07/28/2026 at 15:25, 15 days 14 hours ago Edison Research analyse les solides performances de BB Biotech au deuxième trimestre Stratégie D'investissement Perspectives Du Marché Expansion Du Portefeuille BB Biotech Résultats Du Deuxième Trimestre 2026
BRIEF published on 07/28/2026 at 15:25, 15 days 14 hours ago Edison Research Analyzes BB Biotech's Robust Q2 Performance Investment Strategy Portfolio Expansion Market Outlook BB Biotech Q2 2026 Results
PRESS RELEASE published on 07/28/2026 at 15:20, 15 days 14 hours ago Edison issues report on BB Biotech (BION) Edison issues favorable report on BB Biotech (BION) Q226 results, highlighting NAV growth, portfolio adjustments, and revised payout policy, supporting positive outlook for biotechnology investing Biotechnology Edison Report BB Biotech Q226 Results
BRIEF published on 07/24/2026 at 07:05, 19 days 22 hours ago BB Biotech AG Reports Interim Gains and Adjusts Dividend Policy Dividend Policy Investment Portfolio Interim Report BB Biotech Net Gain
BRIEF published on 07/24/2026 at 07:05, 19 days 22 hours ago BB Biotech AG annonce des résultats intermédiaires et ajuste sa politique de dividendes. Politique De Dividendes Portefeuille D'investissement BB Biotech Rapport Intérimaire Gain Net
BRIEF published on 07/24/2026 at 07:05, 19 days 22 hours ago BB Biotech Q2 2026: Robust NAV Performance Amid Strategic Investments Portfolio Diversification Dividend Policy Strategic Investments M&A Activity Biotechnology Performance
BRIEF published on 07/24/2026 at 07:05, 19 days 22 hours ago BB Biotech T2 2026 : Forte performance de l’actif net grâce à des investissements stratégiques Investissements Stratégiques Politique De Dividendes Diversification Du Portefeuille Activité De Fusions Et Acquisitions Performance En Biotechnologie
PRESS RELEASE published on 07/24/2026 at 07:00, 19 days 22 hours ago EQS-Adhoc: BB Biotech AG publishes its interim report and revises its dividend policy BB Biotech AG publishes its interim report for the first half of 2026, reporting a net gain and revising its dividend policy. Details at www.bbbiotech.ch Financial Results Investment Company Dividend Policy BB Biotech AG Interim Report
PRESS RELEASE published on 07/24/2026 at 07:00, 19 days 22 hours ago BB Biotech Q2 2026: Strong NAV outperformance driven by disciplined stock selection and portfolio positioning BB Biotech AG reports strong NAV outperformance in Q2 2026, driven by disciplined stock selection and portfolio positioning, new investments, and revised dividend policy Dividend Policy BB Biotech AG Stock Selection Q2 2026 NAV Outperformance
BRIEF published on 04/24/2026 at 07:05, 3 months 18 days ago BB Biotech AG Reports Q1 2026 Interim Results Drug Development Net Loss Investment Portfolio BB Biotech Q1 2026
Published on 08/12/2026 at 23:30, 6 hours 27 minutes ago CCL Industries Announces Record Results for 2026 Second Quarter
Published on 08/12/2026 at 23:30, 6 hours 27 minutes ago Bolt Metals to Rebrand as 26 Metals Inc. and Adopt the Ticker "IRON," Highlighting Its Focus on Flagship Florália Iron Project in Brazil's Iron Quadrangle
Published on 08/12/2026 at 23:20, 6 hours 37 minutes ago RJK Explorations Ltd. Announces Upsize of Previously Announced Private Placement
Published on 08/12/2026 at 23:05, 6 hours 52 minutes ago Vox Royalty Reports Q2 2026 Results And Declares Quarterly Dividend
Published on 08/13/2026 at 02:00, 3 hours 56 minutes ago A New Category Is Emerging in the Premium Residential Market — the 'Presidence'
Published on 08/13/2026 at 01:05, 4 hours 51 minutes ago Pepperstone Appoints New CTO to Drive AI-Native Proprietary Tech Push
Published on 08/12/2026 at 21:05, 8 hours 51 minutes ago Aurisco Pharmaceutical is the First Generic Oligonucleotide Manufacturer in the World successfully inspected by USFDA
Published on 08/12/2026 at 19:57, 9 hours 59 minutes ago EQS-Adhoc: Hypoport SE: Hypoport SE resolves share buyback programme with a volume of up to EUR 10 million
Published on 08/12/2026 at 19:37, 10 hours 19 minutes ago EQS-Adhoc: Brockhaus Technologies AG: Preliminary revenue for H1 2026 at €13.4 million and adjusted EBITDA at €-0.5 million; forecast for the continuing operations unchanged
Published on 08/11/2026 at 17:45, 1 day 12 hours ago DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 1 day 12 hours ago Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 2 days 11 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 2 days 11 hours ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
